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ARTICLE
Multi-ancestry genome-wide association study
accounting for gene-psychosocial factor interactions
identifies novel loci for blood pressure traits
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Summary
Psychological and social factors are known to influence blood pressure (BP) and risk of hypertension and associated cardiovascular diseases. To identify novel BP loci, we carried out genome-wide association meta-analyses of systolic, diastolic, pulse, and mean arterial BP,
taking into account the interaction effects of genetic variants with three psychosocial factors: depressive symptoms, anxiety symptoms,
and social support. Analyses were performed using a two-stage design in a sample of up to 128,894 adults from five ancestry groups. In
the combined meta-analyses of stages 1 and 2, we identified 59 loci (p value < 5e8), including nine novel BP loci. The novel associations were observed mostly with pulse pressure, with fewer observed with mean arterial pressure. Five novel loci were identified in
African ancestry, and all but one showed patterns of interaction with at least one psychosocial factor. Functional annotation of the
novel loci supports a major role for genes implicated in the immune response (PLCL2), synaptic function and neurotransmission
(LIN7A and PFIA2), as well as genes previously implicated in neuropsychiatric or stress-related disorders (FSTL5 and CHODL). These findings underscore the importance of considering psychological and social factors in gene discovery for BP, especially in non-European populations.

Introduction
High blood pressure (BP), or hypertension (MIM: 145500),
is a leading risk factor for stroke, cardiovascular disease,
end-stage renal disease, and mortality. By 2025, the number

of adults with hypertension is predicted to reach over 1.5
billion—approximately 30% of the world adult population.1 Hypertension also contributes significantly to health
disparities, with the highest age-adjusted prevalence in the
world attributed to populations of African ancestry.2
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Both genetic and non-genetic influences have been
implicated in the etiology of hypertension. In particular,
genome-wide association studies (GWAS) have identified
over 900 single nucleotide polymorphisms (SNPs) associated with BP traits, mostly in populations of European
ancestry.3 These explain only slightly more than a
quarter of the estimated heritability of BP.3 The remaining unexplained heritability may be due in part to
gene-environment interactions (GxE).4 Thus, incorporating GxE effects in GWAS of BP may yield novel loci

and reveal new insights about the biology of BP regulation and hypertension pathophysiology. Moreover, the
detection of GxE effects may allow us to more precisely
predict individual disease risk in the context of potentially modifiable environmental, lifestyle, and behavioral
risk factors.
The role of psychological and social factors in the etiology
of hypertension is supported by several epidemiological investigations 5,6 and animal model studies.7 For example,
anxiety and depressive symptoms have been consistently
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associated with a higher risk of hypertension.5,8 In a systematic review of 15 prospective cohort studies, individuals
with a high burden of psychological symptoms (anxiety,
depression, and anger) had an 8% higher risk of hypertension compared to those reporting a low burden.9 However,
few studies have investigated potential effect modifications
of genetic factors on BP traits by psychosocial factors.10 To
fill this gap in knowledge, we performed genome-wide association meta-analyses of systolic, diastolic, pulse, and mean
arterial BP in the context of three psychosocial factors—
depressive symptomatology, anxiety symptomatology,
and social support—in a sample of up to 128,894 adults
from five ancestry groups.

Subjects and methods
Study design and participating studies
The study was conducted in the setting of the Gene-Lifestyle Interactions Working Group of the Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) Consortium.11,
12
Study participants included adult men and women aged 18–
80 years from five self-reported ancestry groups: African (AFR),
Asian (ASN), Brazilian admixed (BRA), European (EUR), and His-

panic (HIS). Genome-wide association analyses accounting for
gene-psychosocial factor interactions were carried out using a
two-stage design (Figure 1). Stage 1 comprised up to 31 cohorts,
including up to 68,450 individuals from the five self-reported
ancestry groups. Stage 2 comprised up to 20 cohorts, including
up to 61,046 individuals from four self-reported ancestry
groups: AFR, ASN, EUR, and HIS. Not all studies or participants
had data on all three psychosocial factors, so the number of
participating studies and sample sizes varies for each exposure
analysis (Figure 1). Details about the participating studies are
provided in the Supplemental subjects and methods. Procedures
were in accordance with the ethical standards of the responsible
committee on human experimentation (institutional and national). Each study obtained written informed consent from
the participants and approval from the appropriate institutional
review boards.
To detect novel loci with potentially underlying SNP by
psychosocial factor (SNP 3 Psy) interaction effects, we used two
complementary approaches: (1) both the SNP main effect and
interaction effect on BP levels were jointly assessed using a twodegrees-of-freedom (2-df) test; (2) the effect of interaction alone
was assessed using a 1-df test. When both the SNP main effect
and interaction effect are present, the 2-df is more powerful13
and, thus, may help identify BP-associated loci for which the
1-df test is underpowered.
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Figure 1. Overall study design
For each BP trait, association analyses were
performed taking into account the interaction effects of genetic variants with each of
three psychosocial factors: depressive symptoms (DEPR), anxiety (ANXT), and social
support (SOCS). For each ancestry group,
study-specific results were combined to
perform a 1-degree of freedom (1-df) test
for an interaction effect and a 2-df joint
test of SNP main and interaction effects. Analyses were carried out separately in five selfreported ancestry groups: European (EUR),
African (AFR), Asian (ASN), Hispanic (HIS),
and Brazilian (BRA), and combined in a
trans-ethnic meta-analysis. Sample sizes
for each analysis are shown. Ne, number of
subjects in the exposed strata (E ¼ 1).

Blood pressure traits
Four BP measures were separately modeled: systolic blood pressure
(SBP), diastolic blood pressure (DBP), mean arterial pressure
(MAP), and pulse pressure (PP). SBP and DBP were adjusted for
the BP-lowering effect of antihypertensive medication use by adding 15 and 10 mm Hg, respectively, to the observed BP readings.14
After adjustment, MAP was calculated as two-thirds of DBP plus
one-third of SBP. PP was calculated as the difference between
SBP and DBP. Winsorizing was performed for each BP value that
was more than six standard deviations away from the mean.
Descriptive statistics for the four BP traits in each stage 1 and stage
2 cohort are shown in Table S1.
Psychosocial exposures
Information on depressive symptomatology, anxiety symptomatology, and social support was collected in each participating
study using validated screening questionnaires (Table S2). Each
measure of psychosocial exposure was dichotomized. To harmonize psychosocial exposures assessed using different screening instruments, we used recommended standard cut points specific to
the screening instrument to define high depressive symptoms
and high anxiety symptoms, whereas low social support was
defined based on the lowest quartile of the perceived social support score in each study (all coded as E ¼ 1). Details about the
screening instruments used to measure depressive and anxiety
symptomatology and social support and the cut points used to
define the dichotomous variables in each study are shown in Table
S2. BP readings and psychosocial questionnaires were taken at the
same examination.
Genotype data
All cohorts performed genotyping on Illumina or Affymetrix arrays and imputed to the 1000 Genomes Project reference haplotypes.15 Most studies used the Phase I Integrated Release Version
3 reference panel (2010-11 data freeze, 2012-03-14 haplotypes),
which contains haplotypes for 1,092 individuals of all ethnic
backgrounds.15 Information on genotype and imputation for
each study is presented in Table S3. Although we refer to the
analyzed variants as SNPs, the imputed data also include indels
(insertions and deletions).

4

Study-specific statistical analysis
We considered three statistical models to satisfy slightly different
purposes:12
Model 1 is a joint effect model and is our primary model. It represents the joint analysis of the effects of the SNP, psychosocial
exposure, and their interaction:
E½BP ¼ b0 þ bSNP SNP þ bE E þ bSNPE SNP  E þ bC C
where E is the psychosocial variable and C represents all covariates
(including age, sex, cohort-specific variables, and principal components [PCs]). PCs were derived from the directly measured genotype data and adjusted as appropriate for each study population.
Information on PCs and additional study-specific covariates
included in each analysis is provided in Table S3. Each SNP was
coded under the assumption of an additive model. The model
incorporated a SNP 3 Psy interaction effect. A 2-df joint test was
used to simultaneously evaluate the significance of SNP and SNP
3 Psy effects under the null hypothesis that bSNP ¼ bSNP*E ¼ 0.16
A 1-df test was also used to test for the interaction term alone under the null hypothesis that bSNP*E ¼ 0.
Model 2 is a SNP main effect model:
E½BP ¼ b0 þ bSNP SNP þ bC C
which was analyzed among those measured for the relevant psychosocial factor. Model 2 is used to identify SNPs with main effects
only.
Model 3 is a psychosocial context-dependent SNP main effect
model:
E½BP ¼ b0 þ bSNP SNP þ bE E þ bC C
which estimated the per-allele effect of the SNP on BP adjusting for
an individual psychosocial factor. Model 3 is used to identify SNPs
from the joint model that would be missed when the interaction
term is not used.
Stage 1 cohorts performed ancestry-specific association analyses
using all three models, while stage 2 cohorts performed analyses
using Model 1 only. All association analyses within cohorts were
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performed with various analytical software as described in Table
S3.
Quality control and meta-analyses
Extensive quality control (QC) was performed for both the studyspecific results and the meta-analyses results using EasyQC.17 For
each study, SNPs were filtered out if they had a minor allele frequency (MAF) less than 0.01, a low imputation quality (INFO score
less than 0.5), a discrepancy in MAF compared with the 1000 Genomes reference panel greater than 0.3, or if the product of 2 *
MAF *Nexposed * imputation quality score was less than 20. SNPs in
the European-ancestry and multi-ancestry analyses had to be present in at least three cohorts and 3,000 participants to be reported.
Due to the limited sample sizes, these criteria were relaxed for
other ancestry-specific meta-analysis results, as shown in Table S4.
Inverse-variance weighted fixed-effect meta-analyses were conducted for all 3 models using METAL in stage 1.18 Meta-analyses
of the 2-df joint test and 1-df interaction test in the joint effect
model (model 1) were carried out separately.13 A 1-df Chi-square
test was used to evaluate the 1-df interaction (model 1), SNP
main effect (model 2), and psychosocial factor-adjusted SNP effect
(model 3). A 2-df Wald test was used to jointly test the effects of
both SNP and SNP 3 Psy interaction. Meta-analyses were conducted within each ancestry separately, then combined in a transancestry meta-analysis. Genomic control correction was applied
to the study-specific results and to the ancestry-specific meta-analysis results.19 The quantile-quantile (QQ) plots and the estimated
genomic control inflation factors for both 2-df and 1-df tests in
stage 1 are shown in Figures S1–S6. There was mild to moderate
inflation across most analyses (l 1.1). Variants with p < 1e5
in 1-df or 2-df tests in any meta-analysis and any of the three
models were selected for stage 2 analyses.
In the focused discovery stage 2, only 20,000 variants were
investigated, and we used the same approaches as in stage 1 to
perform ancestry-specific and trans-ancestry meta-analyses but
without genomic control correction or variant filtering. The
20,000 variants were examined for association with the 4 BP
traits, in the context of the 3 psychosocial factors and in each of
the 5 ancestry groups using the joint effect model (model 1).
Finally, we performed ancestry-specific and trans-ancestry metaanalyses of all the cohort-level data from stage 1 and stage 2
together (model 1 only). There was no variant filtering at that
stage, and all available data from stage 1 and stage 2 were used.
We computed false discovery rate (FDR) adjusted p values (qvalues) for the 2-df test using the p.adjust function in R, correcting
for the number of analyses performed in stage 1 (4 BP traits, 3 psychosocial factors, and 5 þ 1 ancestry/trans-ancestry groups). SNPs
with p < 5e8 and q < 0.05 and without any evidence of heterogeneity (pHet > 0.05) in ancestry-specific meta-analyses for either
the 1-df or 2-df test were considered statistically significant.
We defined a locus as the 51 Mbp region surrounding an index
SNP and a novel locus as 51 Mbp away from an index SNP previously reported in the GWAS catalog and in Evangelou et al.3
Proportion of variance explained
We used the VarExp R package20 to estimate the proportion of variance in each BP trait explained by previously reported BP variants
and newly identified SNPs. The pruning threshold was set at r2 ¼
0.2 to trim off redundant contribution from SNPs in high linkage
disequilibrium (LD). Summary statistics and BP-SNP association
estimates were derived from the meta-analyses of stages 1 and 2.
Bioinformatics and functional annotation
We assessed the functional potential of identified SNPs in the
meta-analyses using multiple tools. We first used HaploReg

v4.121 and the Functional Mapping and Annotation (FUMA)22
to annotate the functional features of our novel BP loci. Haploreg
was used to evaluate the effect of the identified SNPs on transcription factor binding site motifs and to perform enhancer enrichment analysis. Specifically, we assessed the overlap of our novel
BP-associated SNPs with predicted enhancers using the
ChromHMM 15-state core model and a binomial test of enrichment relative to the background frequencies of all common variants in 127 cell types. FUMA was used to prioritize candidate genes
at each of the novel BP loci by incorporating three mapping strategies (positional, expression Quantitative Trait Locus (eQTL), and
chromatin interaction mappings), MAGMA gene-set analyses, and
several other annotation tools, such as the Combined Annotation
Dependent Depletion (CADD) score.23 We also used the PhenoScanner v224 database to evaluate our novel BP-associated SNPs
for association with diseases and traits, metabolites (metabolite
quantitative trait loci, mQTL), gene expression (eQTL), proteins
(protein quantitative trait loci, pQTL), and DNA methylation
(methylation quantitative trait loci, methQTL). Finally, we carried
out protein-protein interaction networks and pathways enrichment analyses using STRING v.11.25

Results
Stage 1 analyses comprised up to 68,450 participants from
five ancestry groups (Figure 1). Descriptive statistics of the
studies participating in stage 1 are shown in Table S1. The
proportion of individuals with psychological symptoms
varied by cohort and ancestry group. On average, 16%
(range: 5%–41%) of individuals reported depressive symptoms and 24% (range: 6%–75%) reported anxiety
symptoms.
In stage 1 genome-wide interaction meta-analyses, we
identified 20,323 unique variants with suggestive evidence
(p < 1e5) of any BP trait association with at least one of
the three models tested. These were then evaluated for
BP association in stage 2 in an independent sample of up
to 61,046 individuals from four race/ethnicity groups
(AFR, ASN, EUR, and HIS) (Figure 1).
In meta-analyses combining stage 1 and 2 cohorts, we
identified 1,624 SNPs in 59 loci with genome-wide significant BP associations (p < 5e8) (Table S5). A total of 597
SNPs in 28 loci were associated with SBP, 1,261 SNPs in
26 loci were associated with DBP, 570 SNPs in 26 loci
were associated with MAP, and 150 SNPs in 19 loci were
associated with PP. There were 604 SNPs associated with
more than one BP trait (Figure S7). Almost all (1,614)
SNPs were identified through the 2-df joint test only. Additionally, six SNPs in four loci were identified through the 1df interaction test only, and 4 SNPs in 3 loci were identified
through both. A total of 1,316 SNPs reached genome-wide
significance in more than one association test (Table S5).
Novel BP loci
Among the 59 genome-wide significant loci, 15 SNPs in 9
loci were at least 1 Mbp away from any previously reported
BP locus and therefore considered novel (Table 1; Table S6).
All of them reached genome-wide significance in the 2-df
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Table 1.

Novel loci associated with BP traits discovered in the combined analysis of stages 1 and 2
P.2 df

Q.2 df

P.1 df

HetPValb

Most significant
2-df model

n

1.167

2.34E08

4.81E04

7.82E04

0.338

AA-MAP-DEPR

14,865

1.166

2.05E08

4.24E04

1.45E03

0.364

AA-MAP-DEPR

14,865

1.049

1.39E08

2.96E04

1.03E06

0.794

AA-PP-SOCS

16,406

4.970

0.986

3.01E09

7.16E05

4.58E07

0.753

AA-PP-SOCS

16,406

0.533

4.720

0.941

9.11E09

1.99E04

5.26E07

0.576

AA-PP-SOCS

16,406

0.105

0.301

3.311

0.652

3.63E08

7.08E04

3.75E07

0.665

AA-PP-DEPR

14,534

Effecta

SE

IntEffecta

Locus

Nearest gene

rsID

CHR: position

EA

EAF

MAF AA/EA/HIS/BR/ASN

1

CSF3R

rs77010007

1:37049595

C

0.97

0.03/0/0/0/0

1.721

0.672

3.920

CSF3R

rs112421395

1:37056662

A

0.03

0.03/0/0/0/0

1.864

0.664

3.712

PLCL2

rs60884297

3:17115469

A

0.98

0.02/0/0/0/0

0.106

0.638

5.125

PLCL2

rs111333873

3:17123818

T

0.97

0.03/0/0/0/0

0.004

0.587

PLCL2

rs73153364

3:17135437

T

0.03

0.03/0/0/0/0

0.005

FSTL5

rs138187213

4:162397256

D

0.90

0.10/0.16/0.26/0.19/0.41

2

3

IntSE

FSTL5

rs5863461

4:162403550

D

0.89

0.11/0.16/0.26/0.19/0.41

0.074

0.306

3.321

0.646

2.87E08

5.78E04

2.72E07

0.675

AA-PP-DEPR

14,534

4

CASP8AP2

rs9342214

6:90593029

A

0.91

0.01/0.01/0.12/0.05/0.42

0.055

0.234

2.430

0.453

4.72E09

4.31E05

7.97E08

0.000

TRANS-PP-ANXT

23,157

5

ACA59

rs201673188

11:115004812

D

0.06

0.06/0.25/0.07/0.18/0

0.249

0.440

3.570

0.708

3.86E08

7.48E04

4.53E07

0.169

AA-PP-DEPR

12,882

6

ACSS3

rs140203359

12:81590456

A

0.99

0.01/0.01/0.11/0/0

0.400

0.578

4.444

0.969

3.23E09

3.27E05

4.46E06

0.575

EA-PP-SOCS

32,600

7

SNORD38

rs142313940

13:90434805

A

0.02

0.20/0.02/0.06/0.05/0.25

0.405

0.279

2.586

0.552

4.01E09

3.90E05

2.75E06

0.792

EA-PP-DEPR

76,812

SNORD38

rs150161168

13:90434806

A

0.02

0.21/0.02/0.06/0.05/0.25

0.401

0.279

2.594

0.551

3.87E09

3.80E05

2.55E06

0.787

EA-PP-DEPR

76,812

8

7SK

rs202048896

18:36191432

D

0.96

0.04/0.04/0/0.02/0

0.926

0.520

4.393

0.936

9.86E11

2.81E06

2.67E06

0.241

AA-MAP-DEPR

14,534

9

CHODL

rs73321585

21:19312167

T

0.96

0.08/0/0.02/0.01/0

0.025

0.289

2.670

0.532

1.19E08

9.51E05

5.17E07

0.003

TRANS-MAP-DEPR

37,392

rs73321586

21:19312525

T

0.04

0.08/0/0.02/0.01/0

0.101

0.300

2.773

0.548

3.67E08

2.46E04

4.25E07

0.002

TRANSC-MAP-DEPR

34,421

CHODL
8

SNPs with p < 5 3 10 in the 2-df test or 1-df interaction test and at least 1 Mbp away from any previously reported BP locus are shown. EA, effect allele; EAF, effect allele frequency; MAF, minor allele frequency; SE, standard
error; HetPVal, heterogeneity p value, AA, African ancestry; EUR, European ancestry; HIS, Hispanic ancestry; BR, Brazilian ancestry; ASN, Asian ancestry; df, degrees of freedom; P.2df, P value of the joint test of SNP main effect
and interaction effect with 2 df; Q.2df, false discovery rate q value of the joint test with 2 df; P.1 df, P value of the interaction test with 1 df; TRANS, transethnic meta-analysis; DEPR, depressive symptomatology; ANXT, anxiety
symptomatology; SOCS, social support; PP, pulse pressure; MAP, mean arterial pressure; n, total sample size.
a
SNP main (Effect) and interaction (IntEffect) effects estimated in the joint model. Effect is in mm Hg.
b
p Value for heterogeneity in the stage 1 þ 2 in the most significant 2-df model.

test, and all but one showed suggestive evidence of interaction (1-df p < 0.05/59 ¼ 8.5e4). Indeed, as shown in forest plots (Figures S8–S12), associations at these novel loci
were predominantly driven by interaction effects. Ten of
the newly identified variants were discovered through
modeling of interaction effects with depressive symptomatology, another four with social support, and only one
with anxiety. Except for the two variants in the FSTL5
gene on chromosome 4, the novel variants were of low frequency (MAF, 0.01–0.05) in the population in which they
were identified. Nine of the 15 variants were discovered in
analyses of populations of AFR ancestry. The enhanced discovery of novel loci in AFR ancestry may be due to differences in allele frequencies among ancestry groups. Indeed,
five of the nine variants discovered in analyses of populations of AFR ancestry were not observed in any other
ancestry. Seven of the 15 novel variants were not observed
in individuals of EUR ancestry. Alternatively, SNP 3 Psy
interaction effect sizes may be greater in AFR ancestry.
For example, while rs201673188 is more common in
EUR than AFR, the interaction of SNP with depressive
symptomatology was associated with a decrease in PP of
3.57 mm Hg compared to 0.00 mm Hg in EUR (Table S5).
The two low-frequency variants on chromosome 13 identified in EUR ancestry showed some evidence of BP
association in AFR ancestry, where they were more common (MAF ¼ 0.20) (2-df p ¼ 3.5e3; 1-df p ¼ 2.3e3).
Three novel SNPs were identified in the trans-ancestry
meta-analyses. However, these exhibited significant heterogeneity by ancestry (pHet < 0.016), with significance being driven by results from a single ancestry group
comprising stage 1 cohorts only (Table S7). Further replication of the association of these 3 SNPs with BP is therefore
warranted.
Known BP loci
The remaining 1,609 SNPs reaching genome-wide significance mapped within 1 Mbp of 50 previously reported
BP SNPs. These were mostly identified in European
ancestry samples. Of the 1,609 SNPs, 117 showed nominally significant interaction effects (1-df p < 0.05), and
these were mostly observed in African ancestry samples
or trans-ancestry meta-analyses (Table S5).
We further assessed gene-psychosocial factor interactions
on BP at previously known loci3 in our dataset. Of 983 previously reported BP loci, 976 were present in our meta-analyses of stages 1 and 2. After harmonization of risk alleles
against the previously published results, we tested for interaction in the 976 index SNPs. A Bonferroni-corrected p
value threshold controlling for the number of SNPs tested
(976), the number of BP traits (4), the number of Psy traits
(3), and the number of ancestry groups (5) was used. There
was evidence of gene-psychosocial interaction for 14 known
independent SNPs (1-df p < 0.05/976 3 4 3 3 3 5 ¼
8.5e7), including 9 SNPs reaching genome-wide significance (Table S8). Notably, while these BP loci were identified
from populations of EUR ancestry, the most significant evi-

dence of interaction with psychosocial factors was obtained
in samples of non-EUR ancestry.
Proportion of variance explained
We used ancestry-specific LD-pruned (r2 < 0.2) known and
novel BP SNPs to calculate the percent variance explained
by the SNP main effect and the SNP-psychosocial factor
interaction effect. The highest percent variance explained
was 10.4% for DBP among Asian individuals when the
SNP main effect and anxiety symptoms interactive effects
were jointly modeled (Table S9). Notably, except for populations of EUR ancestry, the percent variance explained by
interaction effects at the identified SNPs was at least equal
to or greater than that explained by the SNP main effects.
This was especially striking in the AFR ancestry group.
Consistently, the percent variance explained by the joint
effects of SNPs and psychosocial factors was 1.3- to 3.7fold greater than that of the SNP main effects across the
4 BP traits, with the greatest difference observed for the
joint effect of SNP 3 depressive symptoms (DEPR) in AFR
ancestry (Table S9).
Functional annotation and gene prioritization
Most newly identified SNPs were annotated as either intronic or intergenic. This suggests evidence of regulatory
mechanisms by which the identified SNPs may influence
BP. Indeed, functional annotation using HaploReg v.4.121
and FUMA22 showed evidence of regulatory motif disruption and overlap with predicted enhancers in major tissue
types for the identified SNPs (Table S10). Enhancer enrichment analysis in HaploReg v.4.121 showed that the strongest signal was in primary natural killer cells from peripheral blood (p ¼ 0.01), suggesting a possible role of innate
immunity as a mechanism underlying these novel associations. Functional annotation was also conducted on all
SNPs in moderate LD (r2 > 0.6) with the identified novel
SNPs (Table S11). Among the 125 SNPs that encompass
the index SNPs and variants in LD, only two were exonic.
These include a stop-loss variant (rs60111091) in PLCL2 in
high LD with the index variant rs111333873 on chromosome 3 (Locus #2). Several SNPs in LD with the novel index
SNPs exhibited high CADD scores, suggesting that they are
likely pathogenic. One SNP with a CADD score of 16.2 and
in complete LD with rs140203359 (Locus #6) was located
in an intron of LIN7A (MIM: 603380). Interestingly,
rs140203359 was also identified as an eQTL for LIN7A in
whole blood (Table S12). Two SNPs with similarly high
CADD scores and in moderately high LD with
rs73321585 (Locus #9) were located in an intron of
CHODL. Chromatin interaction mapping showed significant evidence of long-range interactions of rs60884297
and nearby SNPs (Locus #2) with the promoter of
ANKRD28 (MIM: 611122), DAZL (MIM: 601486), and
PLCL2 (MIM: 614276) in aortic and left ventricular tissues
(Table S13). These three genes were predicted to be highly
intolerant to a loss-of-function mutation (probability of
loss-of-function intolerance (pLI) score > 0.9).
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Figure 2. Enrichment of the prioritized genes mapped to the novel loci in Differentially Expressed Gene (DEG) sets from GTEx v7
data from 53 tissue types
Significantly enriched DEG sets (Bonferroni-corrected p < 0.05) are highlighted in red.

A total of 72 genes were prioritized by FUMA based on their
physical position and their potential role in 3D chromatin
interactions (Table S14). Two additional genes were prioritized via eQTL analysis using PhenoScanner v2 (Table S12).
The 74 prioritized genes showed gene expression enrichment in brain tissue, notably the hypothalamus (Figure 2),
and enrichment in 12 Gene Ontology terms, including
several related to synaptic function (Table S15). We also
used STRING v.1125 to investigate protein-protein interaction networks and pathway enrichment analyses among
the 74 prioritized genes. There was significant evidence of
protein-protein interaction among the prioritized genes (p
¼ 2.5e12). A total of 46 protein-protein interactions were
predicted. These showed enrichment in 4 major Reactome
Pathways, including Neuronal System, Transmission across
Chemical Synapses, Dopamine Neurotransmitter Release,
and Protein-protein Interactions at Synapses (Table S15).

Discussion
This genome-wide association study systematically evaluated the joint effect of SNPs and SNP 3 Psy interactions

8

on BP in a large and diverse sample and identified 59
genome-wide significant loci, of which nine were novel.
Most novel loci were identified in non-European ancestry,
and all but one showed patterns of interaction with at least
one psychosocial factor. The enhanced discovery of novel
loci in non-EUR ancestry was due to population differences
in allele frequencies, with multiple novel variants not
observed in EUR, and/or to population differences in SNP
3 Psy interaction effect sizes.
PP estimates the pulsatile component of BP and is influenced by the stiffness of large arteries and the pattern of
wave reflections.26 In a recent meta-analysis comprising
5,060 white and 3,225 African American healthy adults
from 11 studies, measures of arterial stiffness and wave
reflection were consistently higher in African Americans
than in whites.27 Intriguingly, the majority of the newly
discovered loci were identified from analyses of African
ancestry, with several of the identified variants not observed
in European ancestry. The burden of hypertension in populations of African ancestry is among the highest in the
world and is a primary cause of disparities in cardiovascular
health and life expectancy between African Americans and
whites.28 Psychological and social stressors have been
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associated with hypertension and are thought to play a major role in racial/ethnic differences in hypertension.29 In
particular, several lines of evidence indicate that psychosocial stressors may uniquely impact heart rate variability
among African Americans.29 The findings reported here underscore the value of including diverse populations in discovery of novel BP loci and may provide clues about
possible biological mechanisms underlying the relationships between genes, psychosocial factors, and BP.
Functional annotation of the newly identified loci provides support for a major role of genes implicated in synaptic function, neurotransmission, and innate immunity.
One of the newly identified loci for PP mapped to the
PLCL2 gene region on chromosome 3p24. Three variants
in moderately high LD and polymorphic in samples of African ancestry only were associated at the genome-wide
significance level with PP in the context of social support
and at nominal significance level (p < 0.05) with SBP
and MAP in the context of social support and anxiety.
These variants are in strong LD with a rare stop-loss variant
in the PLCL2 gene and map to a region of long-range chromatin interaction with the PLCL2 promoter in aortic and
left ventricular tissues. PLCL2 encodes a phospholipase
C-like protein that lacks phospholipase catalytic activity.30 PLCL2 is expressed in hematopoietic cells, including
B cells and T cells, and is a negative regulator of B cell receptor signaling and immune responses.31 Genetic variants in
the PLCL2 gene have been associated with several auto-immune disorders32–34 and myocardial infarction35 in GWAS.
The newly identified associations are consistent with the
well-documented role of inflammation and the immune
system in hypertension.36,37
Another newly identified association for PP mapped to
a region on chromosome 12q21 that harbors several genes
involved in synaptic function and plasticity. Lin-7 homolog A (LIN7A) is part of a family of scaffolding proteins
that function as part of a tripartite complex and play a
major role in synaptic function.38 This evolutionarily
conserved complex couples synaptic vesicle exocytosis
to cell adhesion in the brain39 and participates in
NMDA receptor-containing vesicle transport.40 PPFIA2
(MIM: 603143) encodes liprin a2, which organizes presynaptic ultrastructure and controls synaptic output by
regulating synaptic vesicle release.41 SYT1 (MIM:
185605) encodes synaptotagmin 1. The synaptotagmins
are integral membrane proteins of synaptic vesicles
thought to serve as calcium sensors in the process of vesicular trafficking and exocytosis.42
The newly identified locus on chromosome 4 associated
with PP through depressive symptomatology mapped to
an intronic region of the follistatin-like 5 (FSTL5) gene.
This gene encodes a secretory glycoprotein with calciumbinding function. Gene expression analysis of mouse brain
tissue shows that Fstl5 is expressed in the olfactory system,
hippocampal CA3 area, and granular cell layer of the cerebellum.43 Variants in or near this gene have been associated with alcohol-related life events,44 schizophrenia,45

and the clustering of bipolar disorder, major depression,
and schizophrenia.46
The locus on chromosome 21 mapped to an intronic region of the CHODL gene (MIM: 607247), which encodes a
membrane-bound C-type lectin expressed in heart and
skeletal muscle and is involved in muscle organ development. Rare copy number variants in this gene have been
implicated in stress cardiomyopathy, also known as
‘‘broken heart syndrome,’’ a sporadic condition precipitated by psychological or physical stress.47
Strengths of our study include a large sample of community-based cohorts with diverse ancestral backgrounds.
Several limitations must also be acknowledged. First, while
sample size was relatively balanced in the two analysis
stages for populations of European and Asian ancestry,
this was not the case for the other populations. Moreover,
Asian and Brazilian populations were underrepresented in
the overall sample. A more balanced population representation across stages 1 and 2 and a more diverse sample may
have identified additional loci. Second, not all studies
used the same validated instrument to capture depressive
symptomatology, anxiety symptoms, and social support.
This may have introduced some degree of heterogeneity
and thus reduced power of our study. Finally, numerous
studies show that psychological and social stressors are associated with poor health behaviors, such as cigarette smoking, excess alcohol consumption, low physical activity,
and poor diet.48–50 Thus, it is possible that the associations
identified here were mediated at least in part by these factors. Indeed, although none of the nine novel loci identified
here overlap with loci reported in previous GWAS of geneby-alcohol or gene-by-smoking interaction on BP,51,52
several known loci show such an overlap (Table S16).
In conclusion, we identified nine novel loci associated
with BP traits, which harbor genes implicated in the
neuronal system, synaptic function, and the immune
response. Associations of these loci with BP were driven
by interaction effects with at least one of three psychosocial
factors. Moreover, our data highlight the potential for psychosocial factors to modify genetic associations of BP traits
at previously reported loci. These findings underscore the
importance of considering psychological and social factors
in gene discovery for BP, especially in African ancestry.
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STUDY DESCRIPTIONS

Stage 1 cohorts
AGES (Age Gene/Environment Susceptibility Reykjavik Study): The AGES Reykjavik study
originally comprised a random sample of 30,795 men and women born in 1907-1935 and living
in Reykjavik in 1967. A total of 19,381 people attended, resulting in a 71% recruitment rate. The
study sample was divided into six groups by birth year and birth date within month. One group
was designated for longitudinal follow up and was examined in all stages; another was
designated as a control group and was not included in examinations until 1991. Other groups
were invited to participate in specific stages of the study. Between 2002 and 2006, the AGES
Reykjavik study re-examined 5,764 survivors of the original cohort who had participated before
in the Reykjavik Study. The midlife data blood pressure measurement was taken from stage 3 of
the Reykjavik Study (1974-1979), if available. Half of the cohort attended during this period.
Otherwise an observation was selected closest in time to the stage 3 visit. The supine blood
pressure was measured twice by a nurse using a mercury sphygmomanometer after 5 minutes
rest following World Health Organization recommendations.
ARIC (Atherosclerosis Risk in Communities Study): The ARIC study is a population-based
prospective cohort study of cardiovascular disease sponsored by the National Heart, Lung, and
Blood Institute (NHLBI). ARIC included 15,792 individuals, predominantly European American
and African American, aged 45-64 years at baseline (1987-89), chosen by probability sampling
from four US communities. Cohort members completed three additional triennial follow-up
examinations and three additional examinations in 2011-2013 (visit 5), 2016-2017 (visit 6), and
2018-2019 (visit 7). The ARIC study has been described in detail previously (The ARIC
Investigators. The Atherosclerosis Risk in Communities (ARIC) study: Design and objectives.
Am J Epidemiol. 1989; 129:687-702). Blood pressure was measured using a standardized
Hawksley random-zero mercury column sphygmomanometer with participants in a sitting
position after a resting period of 5 minutes. The size of the cuff was chosen according to the arm
circumference. Three sequential recordings for systolic and diastolic blood pressure were
obtained; the mean of the last two measurements was used in this analysis, discarding the first
reading. Blood pressure lowering medication use was recorded from the medication history.
Baependi Heart Study (Brazil): The Baependi Heart Study is an ongoing family-based cohort
conducted in a rural town of the state of Minas Gerais. The study has enrolled approximate 2,200
individuals (over 10% of the town’s adult population) and 10-year follow up period of
longitudinal data. Briefly, probands were selected at random across 11 out of the 12 census
districts in Baependi. After enrolment, the proband's first-degree (parents, siblings, and

offspring), second-degree (half-siblings, grandparents/grandchildren, uncles/aunts,
nephews/nieces, and double cousins), and third-degree (first cousins, great uncles/aunts, and
great nephews/nieces) relatives, and his/her respective spouse's relatives resident both within
Baependi (municipal and rural area) and surrounding towns were invited to participate. Only
individuals age 18 and older were eligible to participate in the study. The study is conducted
from a clinic/office in an easily accessible sector of the town, where the questionnaires were
completed. A broad range of phenotypes ranging from cardiovascular, neurocognitive,
psychiatric, imaging, physiologic and several layers of endophenotypes like metabolomics and
lipidomics have been collected throughout the years Details about follow-up visits and available
data can be found in the cohort profile paper (PMID: 18430212). DNA samples were genotyped
using the Affymetrix 6.0 genechip. After quality control, the data were prephased using
SHAPEIT and imputed using IMPUTE2 based on 1000 Genomes haplotypes.
CARDIA (Coronary Artery Risk Development in Young Adults): CARDIA is a prospective
multicenter study with 5,115 adults Caucasian and African American participants of the age
group 18-30 years, recruited from four centers at the baseline examination in 1985-1986. The
recruitment was done from the total community in Birmingham, AL, from selected census tracts
in Chicago, IL and Minneapolis, MN; and from the Kaiser Permanente health plan membership
in Oakland, CA. The details of the study design for the CARDIA study have been previously
published. Nine examinations have been completed since initiation of the study, respectively in
the years 0, 2, 5, 7, 10, 15, 20, 25 and 30. Written informed consent was obtained from
participants at each examination and all study protocols were approved by the institutional
review boards of the participating institutions. Systolic and diastolic blood pressure was
measured in triplicate on the right arm using a random-zero sphygmomanometer with the
participant seated and following a 5-minutes rest. The average of the second and third
measurements was taken as the blood pressure value. Blood pressure medication use was
obtained by questionnaire.
CHS (Cardiovascular Health Study): CHS is a population-based cohort study of risk factors
for cardiovascular disease in adults 65 years of age or older conducted across four field centers
[PMID: 1669507]. The original predominantly European ancestry cohort of 5,201 persons was
recruited in 1989-1990 from random samples of the Medicare eligibility lists and an additional
predominately African-American cohort of 687 persons was enrolled in 1992-93 for a total
sample of 5,888. Research staff with central training in blood pressure measurement assessed
repeated right-arm seated systolic and diastolic blood pressure levels at baseline with a Hawksley
random-zero sphygmomanometer. Blood samples were drawn from all participants at their
baseline examination and DNA was subsequently extracted from available samples. European
ancestry participants were excluded from the GWAS study sample due to prevalent coronary
heart disease, congestive heart failure, peripheral vascular disease, valvular heart disease, stroke,
or transient ischemic attack at baseline. After QC, genotyping was successful for 3271 European
ancestry and 823 African-American participants. CHS was approved by institutional review
committees at each site and individuals in the present analysis gave informed consent including
consent to use of genetic information for the study of cardiovascular disease.

ERF (Erasmus Rucphen Family study): Erasmus Rucphen Family is a family based study that
includes inhabitants of a genetically isolated community in the South-West of the Netherlands,
studied as part of the Genetic Research in Isolated Population (GRIP) program. [Aulchenko YS,
Heutink P, Mackay I et al: Linkage disequilibrium in young genetically isolated Dutch
population. Eur J Hum Genet 2004; 12: 527–534; Pardo LM, MacKay I, Oostra B, van Duijn
CM, Aulchenko YS: The effect of genetic drift in a young genetically isolated population. Ann
Hum Genet 2005; 69: 288–295].The goal of the study is to identify the risk factors in the
development of complex disorders. Study population includes approximately 3,000 individuals
who are living descendants of 22 couples who lived in the isolate between 1850 and 1900 and
had at least six children baptized in the community church. All data were collected between 2002
and 2005. All participants gave informed consent, and the Medical Ethics Committee of the
Erasmus University Medical Centre approved the study.
FHS (Framingham Heart Study): FHS began in 1948 with the recruitment of an original
cohort of 5,209 men and women (mean age 44 years; 55 percent women). In 1971 a second
generation of study participants was enrolled; this cohort (mean age 37 years; 52% women)
consisted of 5,124 children and spouses of children of the original cohort. A third generation
cohort of 4,095 children of offspring cohort participants (mean age 40 years; 53 percent women)
was enrolled in 2002-2005 and are seen every 4 to 8 years. Details of study designs for the three
cohorts are summarized elsewhere. At each clinic visit, a medical history was obtained with a
focus on cardiovascular content, and participants underwent a physical examination including
measurement of height and weight from which BMI was calculated. Systolic and diastolic blood
pressures were measured twice by a physician on the left arm of the resting and seated
participant using a mercury column sphygmomanometer. Blood pressures were recorded to the
nearest even number. The means of two separate systolic and diastolic blood pressure readings at
each clinic examination were used for statistical analyses.
GENOA (Genetic Epidemiology Network of Arteriopathy): GENOA is one of four networks
in the NHLBI Family-Blood Pressure Program (FBPP). [The FBPP Investigators. Multi-center
genetic study of hypertension: The Family Blood Pressure Program (FBPP). [Hypertension
2002;39:3-9.; Daniels PR, Kardia SL, Hanis CL, Brown CA, Hutchinson R, Boerwinkle E,
Turner ST; Genetic Epidemiology Network of Arteriopathy study. Familial aggregation of
hypertension treatment and control in the Genetic Epidemiology Network of Arteriopathy
(GENOA) study. Am J Med. 2004 May 15;116(10):676-81. PMID: 15121494.] GENOA's longterm objective is to elucidate the genetics of target organ complications of hypertension,
including both atherosclerotic and arteriosclerotic complications involving the heart, brain,
kidneys, and peripheral arteries. The longitudinal GENOA Study recruited European-American
and African-American sibships with at least 2 individuals with clinically diagnosed essential
hypertension before age 60 years. All other members of the sibships were invited to participate
regardless of their hypertension status. Participants were diagnosed with hypertension if they had
either 1) a previous clinical diagnosis of hypertension by a physician with current antihypertensive treatment, or 2) an average systolic blood pressure ≥ 140 mm Hg or diastolic blood
pressure ≥ 90 mm Hg based on the second and third readings at the time of their clinic visit.
Exclusion criteria were secondary hypertension, alcoholism or drug abuse, pregnancy, insulindependent diabetes mellitus, or active malignancy. During the first exam (1995-2000), 1,583

European Americans from Rochester, MN and 1,854 African Americans from Jackson, MS were
examined. Between 2000 and 2005, 1,241 of the European Americans and 1,482 of the African
Americans returned for a second examination. Because African-American probands for GENOA
were recruited through the Atherosclerosis Risk in Communities (ARIC) Jackson field center
participants, we excluded ARIC participants from analyses.
HANDLS (Healthy Aging in Neighborhoods of Diversity across the Life Span): HANDLS is
a community-based, longitudinal epidemiologic study examining the influences of race and
socioeconomic status (SES) on the development of age-related health disparities among a sample
of socioeconomically diverse African Americans and whites. This unique study will assess over
a 20-year period physical parameters and also evaluate genetic, biologic, demographic, and
psychosocial, parameters of African American and white participants in higher and lower SES to
understand the driving factors behind persistent black-white health disparities in overall
longevity, cardiovascular disease, and cognitive decline. The study recruited 3,722 participants
from Baltimore, MD with a mean age of 47.7 years, 2,200 African Americans and 1,522 whites,
with 41% reporting household incomes below the 125% poverty delimiter. Genotyping was done
on a subset of self-reporting African American participants by the Laboratory of Neurogenetics,
National Institute on Aging, National Institutes of Health (NIH). A larger genotyping effort
included a small subset of self-reporting European ancestry samples. This research was
supported by the Intramural Research Program of the NIH, NIA and the National Center on
Minority Health and Health Disparities.
Health ABC (Health, Aging, and Body Composition): Cohort description: The Health ABC
study is a prospective cohort study investigating the associations between body composition,
weight-related health conditions, and incident functional limitation in older adults. Health ABC
enrolled well-functioning, community-dwelling black (n=1281) and white (n=1794) men and
women aged 70-79 years between April 1997 and June 1998. Participants were recruited from a
random sample of white and all black Medicare eligible residents in the Pittsburgh, PA, and
Memphis, TN, metropolitan areas. Participants have undergone annual exams and semi-annual
phone interviews. The current study sample consists of 1559 white participants who attended the
second exam in 1998-1999 with available genotyping data.
Genotyping: Genotyping was performed by the Center for Inherited Disease Research (CIDR)
using the Illumina Human1M-Duo BeadChip system. Samples were excluded from the dataset
for the reasons of sample failure, genotypic sex mismatch, and first-degree relative of an
included individual based on genotype data. Genotyping was successful in 1663 Caucasians.
Analysis was restricted to SNPs with minor allele frequency ≥ 1%, call rate ≥97% and HWE
p≥E-6. Genotypes were available on 914,263 high quality SNPs for imputation based on the
HapMap CEU (release 22, build 36) using the MACH software (version 1.0.16). A total of
2,543,888 imputed SNPs were analyzed for association with vitamin D levels.
HyperGEN (Hypertension Genetic Epidemiology Network): HyperGEN is a family-based
study that looks at the genetic causes of hypertension and related conditions in EA and AA
subjects. HyperGEN recruited hypertensive sibships, along with their normotensive adult

offspring, and an age-matched random sample. HyperGEN has collected data on 2,471
Caucasian-American subjects and 2,300 African-American subjects, from five field centers in
Alabama, Massachusetts, Minnesota, North Carolina, and Utah.
JHS (Jackson Heart Study): The Jackson Heart Study is a longitudinal, community-based
observational cohort study investigating the role of environmental and genetic factors in the
development of cardiovascular disease in African Americans. Between 2000 and 2004, a total of
5301 participants were recruited from a tri-county area (Hinds, Madison, and Rankin Counties)
that encompasses Jackson, MS. Details of the design and recruitment for the Jackson Heart Study
cohort has been previously published. Briefly, approximately 30% of participants were former
members of the Atherosclerosis Risk in Communities (ARIC) study. The remainder were
recruited by either 1) random selection from the Accudata list, 2) commercial listing, 3) a
constrained volunteer sample, in which recruitment was distributed among defined demographic
cells in proportions designed to mirror those in the overall population, or through the Jackson
Heart Study Family Study.
MESA (Multi-Ethnic Study of Atherosclerosis): The Multi-Ethnic Study of Atherosclerosis
(MESA) is a study of the characteristics of subclinical cardiovascular disease and the risk factors
that predict progression to clinically overt cardiovascular disease or progression of the
subclinical disease. MESA consisted of a diverse, population-based sample of an initial 6,814
asymptomatic men and women aged 45-84. 38 percent of the recruited participants were white,
28 percent African American, 22 percent Hispanic, and 12 percent Asian, predominantly of
Chinese descent. Participants were recruited from six field centers across the United States:
Wake Forest University, Columbia University, Johns Hopkins University, University of
Minnesota, Northwestern University and University of California – Los Angeles. Participants are
being followed for identification and characterization of cardiovascular disease events, including
acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and
congestive heart failure; for cardiovascular disease interventions; and for mortality. The first
examination took place over two years, from July 2000 - July 2002. It was followed by five
examination periods that were 17-20 months in length. Participants have been contacted every 9
to 12 months throughout the study to assess clinical morbidity and mortality.
NEO (The Netherlands Epidemiology of Obesity study): The NEO was designed for
extensive phenotyping to investigate pathways that lead to obesity-related diseases. The NEO
study is a population-based, prospective cohort study that includes 6,671 individuals aged 45–65
years, with an oversampling of individuals with overweight or obesity. At baseline, information
on demography, lifestyle, and medical history have been collected by questionnaires. In addition,
samples of 24-h urine, fasting and postprandial blood plasma and serum, and DNA were
collected. Genotyping was performed using the Illumina HumanCoreExome chip, which was
subsequently imputed to the 1000 genome
reference panel. Participants underwent an extensive physical examination, including
anthropometry, electrocardiography, spirometry, and measurement of the carotid artery intimamedia thickness by ultrasonography. In random subsamples of participants, magnetic resonance

imaging of abdominal fat, pulse wave velocity of the aorta, heart, and brain, magnetic resonance
spectroscopy of the liver, indirect calorimetry, dual energy X-ray absorptiometry, or
accelerometry measurements were performed. The collection of data started in September 2008
and completed at the end of September 2012. Participants are currently being followed for the
incidence of obesity-related diseases and mortality.
Pelotas Birth Cohort Study (The 1982 Pelotas Birth Cohort Study, Brazil): The maternity
hospitals in Pelotas, a southern Brazilian city (current population ~330,000), were visited daily in
the year of 1982. The 5,914 liveborns whose families lived in the urban area were examined and
their mothers interviewed. Information was obtained for more than 99% of the livebirths. These
subjects have been followed-up at the following mean ages: 11.3 months (all children born from
January to Abril 1982; n=1457), 19.4 months (entire cohort; n=4934), 43.1 months (entire
cohort; n=4742), 13.1 years (random subsample; n=715), 14.7 years (systematic subsample;
n=1076); 18.2 (male cohorts attending to compulsory Army recruitment examination; n=2250),
18.9 (systematic subsample; n=1031), 22.8 years (entire cohort; n=4297) and 30.2 years (entire
cohort; n=3701). Details about follow-up visits and available data can be found in the two Cohort
Profile papers (PMID: 16373375 and 25733577). DNA samples (collected at the mean age of
22.8 years) were genotyped for ~2.5 million of SNPs using the Illumina HumanOmni2.5-8v1
array (which includes autosomal, X and Y chromosomes, and mitochondrial variants). After
quality control, the data were prephased using SHAPEIT and imputed using IMPUTE2 based on
1000 Genomes haplotypes.
RS (Rotterdam Study): The Rotterdam Study is a prospective, population-based cohort study
among individuals living in the well-defined Ommoord district in the city of Rotterdam in The
Netherlands [Ikram, M.A. et al. The Rotterdam Study: 2018 update on objectives, design and
main results. Eur J Epidemiol 2017, 32:807-850]. The aim of the study is to determine the
occurrence of cardiovascular, neurological, ophthalmic, endocrine, hepatic, respiratory, and
psychiatric diseases in elderly people. The cohort was initially defined in 1990 among
approximately 7,900 persons, aged 55 years and older, who underwent a home interview and
extensive physical examination at the baseline and during follow-up rounds every 3-4 years (RSI). Cohort was extended in 2000/2001 (RS-II, 3,011 individuals aged 55 years and older) and
2006/2008 (RS-III, 3,932 subjects, aged 45 and older). Written informed consent was obtained
from all participants and the Medical Ethics Committee of the Erasmus Medical Center,
Rotterdam, approved the study.
SP2 (Singapore Prospective Study Program): The SP2 is a population-based study of diabetes
and cardiovascular disease in Singapore. It first surveyed subjects (Chinese, Malay and Indian)
from four cross-sectional studies that were conducted in Singapore between 1982 and 1998.
Subjects were between the ages of 24-95 years and represented a random sample of the
Singapore population. Subjects were re-visited between 2003 and 2007. Among the 10,747
individuals who were eligible, 5,157 subjects completed a questionnaire and the subsequent
clinical examinations. Data from this revisit were utilized for this study. Two readings of blood
pressure were taken from participants after 5 min of rest, seated, using an automated blood
pressure monitor (Dinamap Pro100V2; Criticon, Norderstedt, Germany) by trained observers.

One of two cuff sizes (regular, large) was chosen on the basis of the circumference of the
participant’s arm. A third reading was performed if the difference between two readings of either
the systolic blood pressure was greater than 10mmHg or the diastolic blood pressure was greater
than 5mmHg. The mean values of the closest two readings were calculated.
WHI (Women’s Health Initiative): WHI is a long-term national health study that focuses on
strategies for preventing common diseases such as heart disease, cancer and fracture in
postmenopausal women. A total of 161,838 women aged 50–79 years old were recruited from 40
clinical centers in the US between 1993 and 1998. WHI consists of an observational study, two
clinical trials of postmenopausal hormone therapy (HT, estrogen alone or estrogen plus
progestin), a calcium and vitamin D supplement trial, and a dietary modification trial 1. Study
recruitment and exclusion criteria have been described previously 1. Recruitment was done
through mass mailing to age-eligible women obtained from voter registration, driver’s license
and Health Care Financing Administration or other insurance list, with emphasis on recruitment
of minorities and older women 2. Exclusions included participation in other randomized trials,
predicted survival < 3 years, alcoholism, drug dependency, mental illness and dementia. For the
CT, women were ineligible if they had a systolic BP > 200 mm Hg or diastolic BP > 105 mm
Hg, a history of hypertriglyceridemia or breast cancer. Study protocols and consent forms were
approved by the IRB at all participating institutions. Socio-demographic characteristics, lifestyle,
medical history and self-reported medications were collected using standardized questionnaires
at the screening visit. Physical measures of height, weight and blood pressure were measured at a
baseline clinical visit 2. BP was measured by certified staff using standardized procedures and
instruments 3. Two BP measures were recorded after 5 minutes rest using a mercury
sphygmomanometer. Appropriate cuff bladder size was determined at each visit based on arm
circumference. Diastolic BP was taken from the phase V Korotkoff measures. The average of the
two measurements, obtained 30 seconds apart, was used in analyses. The genome wide
association study (GWAS) non-overlapping samples are composed of a case-control study (WHI
Genomics and Randomized Trials Network – GARNET, which included all coronary heart
disease, stroke, venous thromboembolic events and selected diabetes cases that happened during
the active intervention phase in the WHI HT clinical trials and aged matched controls), women
selected to be "representative" of the HT trial (mostly younger white HT subjects that were also
enrolled in the WHI memory study - WHIMS) and the WHI SNP Health Association Resource
(WHI SHARe), a randomly selected sample of 8,515 African American and 3,642 Hispanic
women from WHI. GWAS was performed using Affymetrix 6.0 (WHI-SHARe),
HumanOmniExpressExome-8v1_B (WHIMS), Illumina HumanOmni1-Quad v1-0 B
(GARNET). Extensive quality control (QC) of the GWAS data included alignment (“flipping”)
to the same reference panel, imputation to the 1000G data (using the recent reference panel v3.20101123), identification of genetically related individuals, and computations of principal
components (PCs) using methods developed by Price et al. (using EIGENSOFT software 53),
and finally the comparison with self-reported ethnicity. After QC and exclusions from analysis
protocol, the number of women included in analysis is 4,423 whites for GARNET, 5,202 white
for WHIMS, 7,919 for SHARe African American and 3,377 for SHARe Hispanics.

Stage 2 cohorts
BES (Beijing Eye Study): The BES is a population-based study that assessed the associated and
risk factors of ocular and general diseases in a Chinese population. The study was initialized in
2001 and collected data from 4439 subjects aged ≥ 40 years and living in seven communities in
the Beijing area. Three of these communities were located in rural districts and four were located
in urban districts. The BES was followed-up in 2006, with 3251 of the original subjects
participating, and in 2011, with 2695 subjects returned returning for the follow-up examination.
At the examinations in 2006 and 2011, trained research staffs asked the subjects questions from a
standard questionnaire providing information on family status, level of education, income,
quality of life, psychic depression, physical activity, and known major systemic diseases. Fasting
blood samples were taken for measurement of concentrations of substances such as blood lipids,
glucose, and glycosylated hemoglobin. Individuals were classiﬁed as self-reported non-smokers
or self-reported current smokers. Alcohol consumption habits based on number of drinks per day
were collected. All variables used in analyses were taken from examinations in 2006 or in 2011.
The BES subjects were genotyped on two arrays, Illumina Human610-Quad (N = 832) and
Illumina OmniExpress (N = 814).
CoLaus (Cohorte Lausannoise): The cohort is a random population sample of the city of
Lausanne aged 35-75 years. Recruitment began in June 2003 and ended in May 2006, and the
first follow-up was conducted between April 2009 and September 2012. The CoLaus study was
approved by the Institutional Ethics Committee of the University of Lausanne and informed
consent was appropriately obtained by all participants. Both at baseline and follow-up, all
participants attended the outpatient clinic of the University Hospital of Lausanne in the morning
after an overnight fast. Data were collected by trained field interviewers in a single visit lasting
about 60 min.
DR’s EXTRA (Dose Responses to Exercise Training): The Dose-Responses to Exercise
Training (DR’s EXTRA) Study is a 4-year RCT on the effects of regular physical exercise and
healthy diet on endothelial function, atherosclerosis and cognition in a randomly selected
population sample (n=3000) of Eastern Finnish men and women, identified from the national
population register, aged 55-74 years. Of the eligible sample, 1410 individuals were randomized
into one of the 6 groups: aerobic exercise, resistance exercise, diet, combined aerobic exercise
and diet, combined resistance exercise and diet, or reference group following baseline
assessments. During the four year intervention the drop-out rate was 15%.
GeneSTAR (Genetic Studies of Atherosclerosis Risk): GeneSTAR is a family-based
prospective study of more than 4000 participants begun in 1983 to determine phenotypic and
genetic causes of premature cardiovascular disease. Families were identified from 1983-2006
from probands with a premature coronary disease event prior to 60 years of age who were
identified at the time of hospitalization in any of 10 hospitals in the Baltimore, Maryland area.
Their apparently healthy 30-59 year old siblings without known coronary disease were recruited
and screened between 1983 and 2006. From 2003-2006, adult offspring over 21 years of age of

all participating siblings and probands, as well as the co-parents of the offspring were recruited
and screened. Genotyping was performed in 3,232 participants on the Illumina 1Mv1_c platform.
HCHS/SOL (Hispanic Community Health Study/ Study of Latinos): The HCHS/SOL is a
community-based cohort study of 16,415 self-identified Hispanic/Latino persons aged 18–74
years and selected from households in predefined census-block groups across four US field
centers (in Chicago, Miami, the Bronx, and San Diego). The census-block groups were chosen to
provide diversity among cohort participants with regard to socioeconomic status and national
origin or background. The HCHS/SOL cohort includes participants who self-identified as having
a Hispanic/Latino background; the largest groups are Central American (n = 1,730), Cuban (n =
2,348), Dominican (n = 1,460), Mexican (n = 6,471), Puerto Rican (n = 2,728), and South
American (n = 1,068). The HCHS/SOL baseline clinical examination occurred between 2008 and
2011 and included comprehensive biological, behavioral, and sociodemographic assessments.
Consenting HCHS/SOL subjects were genotyped at Illumina on the HCHS/SOL custom
15041502 B3 array. The custom array comprised the Illumina Omni 2.5M array
(HumanOmni2.5-8v.1-1) ancestry-informative markers, known GWAS hits and drug absorption,
distribution, metabolism, and excretion (ADME) markers, and additional custom content
including ~150,000 SNPs selected from the CLM (Colombian in Medellin, Colombia), MXL
(Mexican Ancestry in Los Angeles, California), and PUR (Puerto Rican in Puerto Rico) samples
in the 1000Genomes phase 1 data to capture a greater amount of Amerindian genetic variation.
QA/QC procedures yielded a total of 12,803 unique study participants for imputation and
downstream association analyses.
HRS (Health & Retirement Study): The Health and Retirement Study (HRS) is a longitudinal
survey of a representative sample of Americans over the age of 50. The current sample is over
26,000 persons in 17,000 households. Respondents are interviewed every two years about
income and wealth, health and use of health services, work and retirement, and family
connections. DNA was extracted from saliva collected during a face-to-face interview in the
respondents' homes. These data represent respondents who provided DNA samples and signed
consent forms in 2006, 2008, and 2010. Respondents were removed if they had missing genotype
or phenotype data.
KORA (Cooperative Health Research in the Augsburg Region): The KORA study is a series
of independent population-based epidemiological surveys of participants living in the region of
Augsburg, Southern Germany. All survey participants are residents of German nationality
identified through the registration office and were examined in 1994/95 (KORA S3) and
1999/2001 (KORA S4). In the KORA S3 and S4 studies 4,856 and 4,261 subjects have been
examined implying response rates of 75% and 67%, respectively. 3,006 subjects participated in a
10-year follow-up examination of S3 in 2004/05 (KORA F3), and 3080 of S4 in 2006/2008
(KORA F4). The age range of the participants was 25 to 74 years at recruitment. Informed
consent has been given by all participants. The study has been approved by the local ethics
committee. Individuals for genotyping in KORA F3 and KORA F4 were randomly selected and
these genotypes are taken for the analysis of the phenotypes in KORA S3 and KORA S4.

LBC1921 (Lothian Birth Cohort 1921): LBC1921 (http://www.lothianbirthcohort.ed.ac.uk/)
consists of 550 (234 male) relatively healthy individuals, assessed on cognitive and medical traits
at a mean age of 79.1 years (SD = 0.6). They were born in 1921, most took part in the Scottish
Mental Survey of 1932, and almost all lived independently in the Lothian region (Edinburgh City
and surrounding area) of Scotland.
LBC1936 (Lothian Birth Cohort 1936): LBC1936 (http://www.lothianbirthcohort.ed.ac.uk/)
consists of 1091 (548 male) relatively healthy individuals who underwent cognitive and medical
testing at a mean age of 69.6 years (SD = 0.8). They were born in 1936, most took part in the
Scottish Mental Survey of 1947, and almost all lived independently in the Lothian region of
Scotland.
Lifelines (Netherlands Biobank): Lifelines (https://lifelines.nl/) is a multi-disciplinary
prospective population-based cohort study using a unique three-generation design to examine the
health and health-related behaviors of 165,000 persons living in the North East region of The
Netherlands. It employs a broad range of investigative procedures in assessing the biomedical,
socio-demographic, behavioral, physical and psychological factors which contribute to the health
and disease of the general population, with a special focus on multimorbidity. In addition, the
Lifelines project comprises a number of cross-sectional sub-studies which investigate specific
age-related conditions. These include investigations into metabolic and hormonal diseases,
including obesity, cardiovascular and renal diseases, pulmonary diseases and allergy, cognitive
function and depression, and musculoskeletal conditions. All survey participants are between 18
and 90 years old at the time of enrollment. Recruitment has been going on since the end of 2006,
and over 130,000 participants had been included by April 2013. At the baseline examination, the
participants in the study were asked to fill in a questionnaire (on paper or online) before the first
visit. During the first and second visit, the first or second part of the questionnaire, respectively,
are checked for completeness, a number of investigations are conducted, and blood and urine
samples are taken. Lifelines is a facility that is open for all researchers. Information on
application and data access procedure is summarized on www.lifelines.nl.
NESDA (Netherlands Study of Depression and Anxiety): NESDA is a multi-center study
designed to examine the long-term course and consequences of depressive and anxiety disorders
(http://www.nesda.nl). NESDA included both individuals with depressive and/or anxiety
disorders and controls without psychiatric conditions. Inclusion criteria were age 18-65 years and
self-reported western European ancestry while exclusion criteria were not being fluent in Dutch
and having a primary diagnosis of another psychiatric condition (psychotic disorder, obsessive
compulsive disorder, bipolar disorder, or severe substance use disorder).
SHIP (Study of Health in Pomerania): The Study of Health In Pomerania (SHIP) is a
prospective longitudinal population-based cohort study in Mecklenburg-West Pomerania
assessing the prevalence and incidence of common diseases and their risk factors (PMID:
20167617). SHIP encompasses the two independent cohorts SHIP and SHIP-TREND.

Participants aged 20 to 79 with German citizenship and principal residency in the study area
were recruited from a random sample of residents living in the three local cities, 12 towns as well
as 17 randomly selected smaller towns. Individuals were randomly selected stratified by age and
sex in proportion to population size of the city, town or small towns, respectively. A total of
4,308 participants were recruited between 1997 and 2001 in the SHIP cohort. Between 2008 and
2012 a total of 4,420 participants were recruited in the SHIP-TREND cohort. Individuals were
invited to the SHIP study center for a computer-assisted personal interviews and extensive
physical examinations. The study protocol was approved by the medical ethics committee of the
University of Greifswald. Oral and written informed consents was obtained from each of the
study participants
SWHS/SMHS (Shanghai Women's Health Study/ Shanghai Men's Health Study): The
Shanghai Women's Health Study (SWHS) is an ongoing population-based cohort study of
approximately 75,000 women who were aged 40-70 years at study enrollment and resided in in
urban Shanghai, China; 56,832 (75.8%) provided a blood samples. Recruitment for the SWHS
was initiated in 1997 and completed in 2000. The self-administered questionnaire includes
information on demographic characteristics, disease and surgery histories, personal habits (such
as cigarette smoking, alcohol consumption, tea drinking, and ginseng use), menstrual history,
residential history, occupational history, and family history of cancer.
The blood pressure were measured by trained interviewers (retired nurses) with a conventional
mercury sphygmomanometer according to a standard protocol, after the participants sat quietly
for 5 min at the study recruitment. Included in the current project were 2970 women who had
GWAS data and blood pressure measurements at the baseline interview or 892 women who had
GWAS data and lipids data. The Shanghai Men’s Health Study (SMHS) is an ongoing
population-based cohort study of 61,480 Chinese men who were aged between 40 and 74 years,
were free of cancer at enrollment, and lived in urban Shanghai, China; 45,766 (74.4%) provided
a blood samples. Recruitment for the SMHS was initiated in 2002 and completed in 2006. The
self-administered questionnaire includes information on demographic characteristics, disease and
surgery histories, personal habits (such as cigarette smoking, alcohol consumption, tea drinking,
and ginseng use), residential history, occupational history, and family history of cancer. The
blood pressure were measured by trained interviewers (retired nurses) with a conventional
mercury sphygmomanometer according to a standard protocol, after the participants sat quietly
for 5 min at the study recruitment. Included in the current project were 892 men who had GWAS
data and blood pressure measurements at the baseline interview or 298 men who had GWAS
data and lipids data.
TRAILS (Tracking Adolescents’ Individual Lives Survey): TRAILS is a prospective cohort
study of Dutch adolescents and young adults, with bi- or triennial measurements from age 11
onwards, which started in 2001. TRAILS consists of a general population and a clinical cohort
(https://www.trails.nl/en/home). In the population cohort, six assessment waves have been
completed to date, at mean ages 11.1 (SD = 0.6), 13.6 (SD = 0.5), 16.3 (SD = 0.7), 19.1 (SD =
0.6), 22.3 (SD = 0.6), and 25.8 (SD = 0.6). Data for the present study were collected in the
population cohort only, during the third assessment wave. The study was approved by the Dutch
Central Committee on Research Involving Human Subjects.

YFS (The Cardiovascular Risk in Young Finns Study): The YFS is a population-based follow
up study started in 1980. The main aim of the YFS is to determine the contribution made by
childhood lifestyle, biological and psychological measures to the risk of cardiovascular diseases
in adulthood. In 1980, over 3,500 children and adolescents all around Finland participated in the
baseline study. The follow-up studies have been conducted mainly with 3-year intervals. The
latest 30-year follow-up study was conducted in 2010-11 (ages 33-49 years) with 2,063
participants. The study was approved by the local ethics committees (University Hospitals of
Helsinki, Turku, Tampere, Kuopio and Oulu) and was conducted following the guidelines of the
Declaration of Helsinki. All participants gave their written informed consent.
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Figure S1. Quantile-quantile (QQ) plots for each of the BP-Psychosocial factor combinations for Stage 1 studies of
African ancestry. The observed -log10(P-values) are plotted against the expected -log10(P-values). The joint 2-df test pvalues are shown in black. The 1-df interaction p-values are shown in red.

Figure S2. Quantile-quantile (QQ) plots for each of the BP-Psychosocial factor combinations for Stage 1 studies of
European ancestry. The observed -log10(P-values) are plotted against the expected -log10(P-values). The joint 2-df test pvalues are shown in black. The 1-df interaction p-values are shown in red.

Figure S3. Quantile-quantile (QQ) plots for each of the BP-Psychosocial factor combinations for Stage 1 Brazilian
cohorts. The observed -log10(P-values) are plotted against the expected -log10(P-values). The joint 2-df test p-values are
shown in black. The 1-df interaction p-values are shown in red.

Figure S4. Quantile-quantile (QQ) plots for each of the BP-Psychosocial factor combinations for Stage 1 studies of
Hispanic ancestry. The observed -log10(P-values) are plotted against the expected -log10(P-values). The joint 2-df test pvalues are shown in black. The 1-df interaction p-values are shown in red.

Figure S5. Quantile-quantile (QQ) plots for each of the BP-Psychosocial factor combinations for Stage 1 studies of Asian
ancestry. The observed -log10(P-values) are plotted against the expected -log10(P-values). The joint 2-df test p-values are
shown in black. The 1-df interaction p-values are shown in red.

Figure S6. Quantile-quantile (QQ) plots for each of the BP-Psychosocial factor combinations for the transethnic metaanalysis of Stage 1 cohorts. The observed -log10(P-values) are plotted against the expected -log10(P-values). The joint 2df test p-values are shown in black. The 1-df interaction p-values are shown in red.

Figure S7. Venn diagram showing the distribution of genome-wide significant associations among the 1624
identified SNPs across BP traits.

Figure S8. Forest plots of the novel SNPs associated with MAP in AA in the context of DEPR. SNP main effects (black)
and interaction effects (red) are shown for stage 1, stage 2, and stage 1+ 2 combined. Note that the meta-analysis of Stage
1 and Stage 2 cohorts did not include the stringent variant filtering strategy used for Stage 1. Rather it uses all available
data. As a result, the N of Stage 1+2 is always larger than that of N of the individual meta-analyses at each Stage.

Figure S9. Forest plots of the novel SNPs associated with PP in AA in the context of SOCS. SNP main effects (black)
and interaction effects (red) are shown for stage 1, stage 2, and stage 1+ 2 combined. Note that the meta-analysis of Stage
1 and Stage 2 cohorts did not include the stringent variant filtering strategy used for Stage 1. Rather it uses all available
data. As a result, the N of Stage 1+2 is always larger than that of N of the individual meta-analyses at each Stage.

Figure S10. Forest plots of the novel SNPs associated with PP in AA in the context of DEPR. SNP main effects (black)
and interaction effects (red) are shown for stage 1, stage 2, and stage 1+ 2 combined. Note that the meta-analysis of Stage
1 and Stage 2 cohorts did not include the stringent variant filtering strategy used for Stage 1. Rather it uses all available
data. As a result, the N of Stage 1+2 is always larger than that of N of the individual meta-analyses at each Stage.

Figure S11. Forest plots of the novel SNPs associated with PP in EA in the context of DEPR or SOCS. SNP main effects
(black) and interaction effects (red) are shown for stage 1, stage 2, and stage 1+ 2 combined. Note that the meta-analysis
of Stage 1 and Stage 2 cohorts did not include the stringent variant filtering strategy used for Stage 1. Rather it uses all
available data. As a result, the N of Stage 1+2 is always larger than that of N of the individual meta-analyses at each
Stage.

Figure S12. Forest plots of the novel SNPs associated with PP or MAP in the transethnic meta-analysis. SNP main effects
(black) and interaction effects (red) are shown for stage 1, stage 2, and stage 1+ 2 combined. Note that the meta-analysis
of Stage 1 and Stage 2 cohorts did not include the stringent variant filtering strategy used for Stage 1. Rather it uses all
available data. As a result, the N of Stage 1+2 is always larger than that of N of the individual meta-analyses at each
Stage.

